Advertisement

Image-Guided Prostate Cancer Therapy Using Aptamer-Functionalized Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles

Authors

  • Mi Kyung Yu,

    1. Cell Dynamics Research Center, Research Center for Biomolecular Nanotechnology, School of Life Sciences, Gwangju Institute of Science and Technology, 261 Chemdangwagi-ro, Gwangju 500–712, Republic of Korea
    Search for more papers by this author
  • Dongkyu Kim,

    1. Division of Magnetic Resonance, Korea Basic Science Insititute, 804–1 Ochang-eup, Chungbuk 363–883, Republic of Korea
    Search for more papers by this author
  • In-Hyun Lee,

    1. Cell Dynamics Research Center, Research Center for Biomolecular Nanotechnology, School of Life Sciences, Gwangju Institute of Science and Technology, 261 Chemdangwagi-ro, Gwangju 500–712, Republic of Korea
    Search for more papers by this author
  • Jee-Soo So,

    1. Cell Dynamics Research Center, Research Center for Biomolecular Nanotechnology, School of Life Sciences, Gwangju Institute of Science and Technology, 261 Chemdangwagi-ro, Gwangju 500–712, Republic of Korea
    Search for more papers by this author
  • Yong Yeon Jeong,

    1. Department of Diagnostic Radiology, Jeonnam National University Hwasun Hospital, 160 Ilsim-ri, Hwasun-eup, Jeonnam 519–809, Republic of Korea
    Search for more papers by this author
  • Sangyong Jon

    Corresponding author
    1. Cell Dynamics Research Center, Research Center for Biomolecular Nanotechnology, School of Life Sciences, Gwangju Institute of Science and Technology, 261 Chemdangwagi-ro, Gwangju 500–712, Republic of Korea
    • Cell Dynamics Research Center, Research Center for Biomolecular Nanotechnology, School of Life Sciences, Gwangju Institute of Science and Technology, 261 Chemdangwagi-ro, Gwangju 500–712, Republic of Korea.
    Search for more papers by this author

Abstract

CG-rich duplex containing prostate-specific membrane antigen (PSMA) aptamer-conjugated thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPIONs) is reported as prostate cancer-specific nanotheranostic agents. These agents are capable of prostate tumor detection in vivo by magnetic resonance imaging (MRI) and selective delivery of drugs to the tumor tissue, simultaneously. The prepared PSMA-functionalized TCL-SPION via a hybridization method (Apt–hybr–TCL-SPION) exhibited preferential binding towards target prostate-cancer cells (LNCaP, PSMA+) in both in vitro and in vivo when analyzed by T2-weighted MRI. After Dox molecules were loaded onto the Apt–hybr–TCL-SPION through the intercalation of Dox to the CG-rich duplex containing PSMA aptamer as well as electrostatic interaction between the Dox-and-polymer coating layer of the nanoparticles, the resulting Dox@Apt–hybr–TCL-SPION showed selective drug-delivery efficacy in the LNCaP xenograft mouse model. These results suggest that Dox@Apt–hybr–TCL-SPION has potential for use as novel prostate cancer-specific nanotheranostics.

Ancillary